There is a significant, inverse, dose-response relationship between usage of pre-exposure prophylaxis (PrEP) and HIV diagnosis rates, according to a large, long-term, state-by-state analysis published in The Lancet HIV. The findings are our clearest real-world evidence to date that PrEP works to curb HIV at the population level—and that we still have very far to go in making use of its potential, particularly for people of color.
Highlighted Study Population and Methods
This study assessed PrEP use, HIV viral suppression, and trends in HIV diagnoses in all U.S. states and the District of Columbia using a nationwide commercial pharmacy database (IQVIA).
PrEP coverage (measured as PrEP users per 100 people with a PrEP indication) and HIV diagnoses (based on public health surveillance data) were calculated by state for each year from 2012 through 2022. States were grouped into quintiles by their degree of change in HIV diagnosis rates.
After controlling for state-specific viral suppression, the authors calculated state- and national-level associations of PrEP coverage with HIV diagnosis rates.
Read the full news story at TheBodyPro.
Source : TheBodyPro
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.